This content is PDF only. Please click on the PDF icon to access.
On 4 June 1970 the Food and Drug Administration approved two new drug applications for levodopa, to be used in treatment of Parkinson's disease and syndrome.
Distribution of the drug will be limited for an indefinite period to neurological clinics and hospitals affiliated with medical schools and to clinical investigators. As production facilities increase and therapeutic experience accumulates, the drug will be distributed more widely.
The rationale for the use of levodopa in the treatment of Parkinson's disease is based on studies published from 1958 to 1960. They showed that dopamine, which normally occurred in high concentration
Current Drug Information: Levodopa. Ann Intern Med. ;73:445–447. doi: 10.7326/0003-4819-73-3-445
Download citation file:
Published: Ann Intern Med. 1970;73(3):445-447.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use